Snake Grass: The Cancer Claim

If you are reading this page while making a treatment decision for yourself or someone you love, read the verdict section first. This page exists because a lot of people in Malaysia and Indonesia between roughly 2010 and 2015 made that decision on the strength of word of mouth rather than the record below, and some of them lost time they could not get back. Everything on this page is real, published, peer-reviewed research about this plant and cancer — the point is not that there is nothing here. The point is being exact about what tier of evidence each finding belongs to, because the tiers do not add up to what the folk reputation implies.

Table of Contents

  1. How the Belief Took Hold
  2. Tier 1: Cell Culture — Breadth Without Depth
  3. Tier 2: Two Real Mouse Tumour Studies
  4. Tier 3: The One Real Clinical Trial — And What It Actually Tested
  5. What Has Never Been Done
  6. The Chemotherapy Interaction Problem
  7. The Measured Harm: Delay and Refusal
  8. Verdict
  9. What a Real Cancer Trial Would Need to Show
  10. Key Research Papers
  11. Connections

How the Belief Took Hold

Snake grass is cheap, fast-growing, and can be propagated from a cutting in a pot on a balcony — unlike tongkat ali, which takes years to produce a harvestable root, or a pharmaceutical, which costs money and requires a diagnosis to access. Word of mouth and social media carried stories of remission credited to blended-leaf juice, plants were given away between neighbours, and by the early 2010s drinking large daily quantities of fresh leaf juice alongside, or occasionally instead of, oncology treatment had become common enough in Malaysia and Singapore to draw attention from clinicians and the press. None of that history is evidence about whether the plant does anything to a tumour. It explains why the belief is strong; it says nothing about whether the belief is correct. The rest of this page is only about the second question.

Tier 1: Cell Culture — Breadth Without Depth

The laboratory literature is genuinely large. A live search for Clinacanthus nutans together with cancer-related terms returns roughly sixty indexed records, and the range of cancer types tested against is wide: breast (MCF-7, T47D, MDA-MB-231, triple-negative lines), cervical (SiHa, HeLa), lung (A549), colon, pancreatic, renal, prostate, oral squamous, melanoma (D24), and lymphoma (SUP-T1). Extracts, fractions and isolated compounds have shown cytotoxicity, apoptosis induction, and effects on named signalling pathways — Notch1 in cervical cancer stem-like cells, PDE3B/Apelin signalling in a colon cancer model, FOXO4/TNFSF15/caspase-9 activation in HeLa cells, and more.

Every one of these is cells in a dish, or a molecular docking simulation. That matters more than it sounds like it should, for a specific reason worth stating plainly: killing cancer cells in a culture well is not a hard bar to clear. Bleach does it. Concentrated salt does it. Large numbers of plant extracts do it, at concentrations reached by direct application that a swallowed drink, filtered through digestion, liver metabolism, and a blood-tumour barrier, would never achieve inside a person. The gap between “cytotoxic in vitro” and “effective in a patient” is one of the most consistently disappointing gaps in all of oncology drug development, and it is why cell-culture results are treated as a first filter, not a finding, everywhere cancer drugs are actually developed.

The researchers who work most closely with this exact plant say so themselves, more bluntly than most secondary summaries do. Hii and colleagues, testing C. nutans extracts against six human cancer cell lines including pancreatic ductal adenocarcinoma, found the extracts alone could not produce potent anti-proliferative effects in most lines tested, and wrote in their own conclusion that their results “provide strong evidence of C. nutans extracts being inefficacious as monotherapy for cancer. Hence, it should not be used as a total substitution for any chemotherapy agents.” Widjaja and colleagues, testing extracts against breast cancer cell lines MCF7 and T47D, likewise reported low cytotoxic effects from the extracts alone. These are not hostile outside critics; they are the plant’s own researchers, publishing in journals sympathetic enough to this line of study to keep testing it, reporting that on its own, in the assay that most favours a positive result, it does not do very much.

Back to Table of Contents

Tier 2: Two Real Mouse Tumour Studies

This is the tier most summaries of this plant — both promotional and sceptical — skip past, and it deserves more attention than it gets, in both directions. It is a real step up from a culture dish: a living immune system, real drug distribution and metabolism, and an actual measured tumour.

Nik Abd Rahman and colleagues (2019) gave a methanol leaf extract to mice bearing 4T1 breast tumours, a standard immunocompetent mouse breast-cancer model, at two doses (200 mg/kg and 1000 mg/kg). Both doses significantly reduced blood markers of oxidative stress (nitric oxide and malondialdehyde, p<0.05). The higher dose significantly reduced the number of actively dividing tumour cells, tumour weight, and tumour volume, with no adverse effect on spleen immune-cell activity at either dose. The same high dose also reduced the number of tumour colonies recovered from liver and lung tissue — a marker of metastatic spread — which, if it holds up, is arguably the more interesting result of the two. The authors’ own conclusion calls this “an effective and complementary approach for cancer prevention and treatment” — their word, not this page’s, and worth noting precisely because “complementary” is not “alternative to.”

Huang and colleagues (2015) gave a 30% ethanol leaf extract to mice with induced hepatoma (liver tumours). The extract significantly reduced tumour volume and weight, and tissue analysis (TUNEL staining, PARP and caspase-3 cleavage, BAX/Bcl-2 ratio) confirmed the tumour cells were undergoing programmed cell death rather than simply failing to grow. The mechanistic finding worth pulling out: treated mice showed more IFN-γ-producing T cells and fewer IL-4-producing T cells, with higher serum IFN-γ and IL-2 — a shift toward a Th1-dominant immune profile. This is a real, biologically coherent antitumour signal working through the immune system rather than through direct poisoning of tumour cells, and it lines up with an entirely separate finding covered on the mechanism page: isolated C. nutans phytosterols independently push T-helper cytokine balance in the same Th1-favouring direction in cell culture. Two different research groups, two different experimental systems, converging on the same immunological direction is a more persuasive pattern than either result alone — and it is still two rodent-and-cell-culture findings, not a demonstrated effect in a person.

What this tier does and does not establish. It establishes that, in living animals, at specific doses, under specific tumour models, an extract of this plant measurably slowed tumour growth through at least two plausible and partly independent mechanisms (direct apoptosis induction, and immune modulation). It does not establish that either mechanism operates the same way in a human at any achievable oral dose, and it emphatically does not establish anything about whether it would do so instead of chemotherapy or radiotherapy — a question these studies were not designed to ask, because neither mouse model received standard cancer treatment in either arm for comparison. Mouse tumour models are also, as a category, notorious for showing effects that do not reproduce in human trials; a large fraction of compounds that shrink mouse tumours never become a working human cancer drug, for reasons ranging from dose scaling to the biological differences between an implanted mouse tumour and a naturally arising human one. Real evidence, correctly placed: better than a dish, nowhere near a patient.

Back to Table of Contents

Tier 3: The One Real Clinical Trial — And What It Actually Tested

Here is the finding this page most wants a careful reader to sit with, because it is easy to summarise wrong in either direction. There is exactly one registered randomised controlled trial of a Clinacanthus nutans preparation in cancer patients that this page’s search of the indexed literature found (trial registration NCT03359187, Kongwattanakul and colleagues, 2022). It is a real RCT, at a real hospital (Chulabhorn Hospital, Bangkok), in 120 actual cancer patients.

What it tested: a C. nutans (“payayor”) mouthwash, a fingerroot (Boesenbergia rotunda) mouthwash, and standard normal saline with sodium bicarbonate, compared head-to-head for preventing radiation-induced oral mucositis — the painful mouth inflammation that is a common side effect of head-and-neck radiotherapy — in patients already undergoing that radiotherapy for their cancer.

What it did not test: anything about the cancer itself. This trial has nothing to say about tumour size, cancer progression, remission, or survival. It is a supportive-care trial, comparing three mouth rinses for a treatment side effect, in patients who were all receiving standard oncology care throughout.

What it found: all three mouthwashes performed similarly. Average mucositis severity scores stayed below 2 (on the assessment scale used) in every arm. The herbal mouthwashes delayed the onset of mucositis slightly compared with saline, but the difference was not statistically significant. Body mass index and patient satisfaction were comparable across all three groups, with no clear preference expressed for any of them. The authors’ own conclusion is that a herbal mouthwash “could substitute” the current saline-and-bicarbonate standard — substitute, in the sense of being an equally reasonable option, not superior to it.

So: the one real clinical trial of this plant in cancer patients is a supportive-care, non-inferiority-flavoured comparison for a treatment side effect, and even there the result was a tie rather than a win. That is a completely different claim from “treats cancer,” and it is worth stating clearly that this trial existing at all does not change the answer to the question people are actually asking when they reach for this plant instead of, or alongside, oncology treatment for the tumour itself.

Back to Table of Contents

What Has Never Been Done

Stated as plainly as the evidence search allows: no randomised controlled trial, no non-randomised clinical trial, and no published case series with objective tumour-response measurement has ever tested whether Clinacanthus nutans, in any preparation, shrinks a human tumour, extends progression-free survival, or extends overall survival, in any cancer, at any stage. Not one. The literature search behind this page, run directly against PubMed with species-locked terms rather than assumed from a review article, found extensive cell culture work, two real mouse tumour studies, and one real supportive-care trial for a treatment side effect — and nothing at all at the level of evidence oncology actually uses to decide whether a treatment works.

This is worth restating because “there is no clinical trial evidence” is sometimes read as a rhetorical flourish rather than a literally accurate description of a literature search. Here it is literally accurate, checked directly, as of this page’s writing.

Back to Table of Contents

The Chemotherapy Interaction Problem

This is where a laboratory finding that sounds encouraging in one framing becomes a genuine safety concern in another, because it is the same mechanism described twice. Quah and colleagues tested C. nutans extracts for cytochrome P450 inhibitory activity and found real inhibition of this enzyme family in laboratory assay. The cytochrome P450 system is how the liver clears the majority of prescription drugs, including most chemotherapy agents, from the bloodstream — inhibit it, and drug levels can rise unpredictably above the dose a patient was actually prescribed.

Separately, and for a different reason, two research groups have specifically combined C. nutans extract with real chemotherapy drugs in cell culture and found the combination more potent than the chemotherapy drug alone: Hii and colleagues found stem extract allowed a 2.38– to 5.28-fold reduction in the gemcitabine dose needed to achieve the same pancreatic-cancer-cell killing, and Widjaja and colleagues found one specific extract-and-doxorubicin combination outperformed doxorubicin alone in breast cancer cells. Both research groups frame this as a potentially useful synergy worth investigating further — and in a monitored clinical trial setting, with controlled doses and blood levels checked, that framing would be reasonable.

Nobody drinking blended leaf juice at home while on oral or infused chemotherapy is in a monitored clinical trial. An unmeasured plant extract that plausibly potentiates chemotherapy drugs through more than one mechanism at once — a metabolic-clearance mechanism (CYP450) and an apoptosis-pathway mechanism (the gemcitabine and doxorubicin work) — sitting on top of a standard chemotherapy dose calculated without any allowance for it, is a plausible route to increased toxicity rather than a free efficacy bonus. The same property that makes this plant scientifically interesting as a chemotherapy adjunct is the property that makes uncoordinated use genuinely risky. This is not a reason to fear the plant; it is a reason anyone on chemotherapy who is also taking snake grass, in any preparation, needs to tell their oncology team specifically, so drug levels and side effects can be watched for.

Back to Table of Contents

The Measured Harm: Delay and Refusal

The realistic harm from this plant was never poisoning. Snake grass is a mild, non-toxic leafy plant at ordinary intakes (see the main page’s cautions for the upper-end caveats on very large juice quantities). The harm is what happens when a treatable cancer is given time to become a less treatable one.

This is not a species-specific finding — no study has followed a cohort of snake-grass users specifically to measure their cancer survival, and this page will not pretend one exists. What does exist is a broader, well-established oncology literature on complementary and alternative medicine use around conventional cancer treatment, and it is unambiguous about the direction of the risk. Johnson and colleagues, analysing a large US cancer registry, found that patients with curable cancers (breast, prostate, lung, colorectal) who used complementary medicine alongside refusing at least one component of conventional treatment had more than double the risk of death at five years compared with those who received conventional treatment alone — and that the excess risk was concentrated specifically in those who refused conventional therapy, not in complementary-medicine use by itself. Older case-series work on breast cancer patients who declined evidence-based treatment, and on those who used alternative therapy as primary treatment, found the same direction: delay and substitution cost survival, in a disease where stage at treatment is often the single biggest determinant of outcome. Malaysian survey data separately confirms that complementary and alternative medicine use is common among cancer patients in Malaysian hospitals, most often for managing treatment side effects rather than replacing treatment outright — which is the safer pattern, and the one this page’s tier-3 trial actually speaks to.

Stage-dependence is the mechanism, and it is brutal rather than gradual: many cancers curable at diagnosis are markedly less curable a year later, and a year is not a long time to spend waiting to see whether leaf juice is working before returning to oncology care.

Back to Table of Contents

Verdict

Using this site’s three-tier evidence language: the claim that Clinacanthus nutans treats human cancer is ABSENT evidence — not negative, because nothing has been properly tested against a tumour and failed; not old-weak-and-positive, because there is no clinical trial of any age or quality testing this question; simply never adequately tested in a human being, at any phase, for any cancer. That is the correct, precise, checkable description, and it is a different statement from either “it cures cancer” or “there is nothing here.”

What is not absent: a real, broad, methodologically ordinary cell-culture literature; two real dose-dependent mouse tumour studies with a biologically coherent and partly cross-validated immune mechanism; one real clinical trial in actual cancer patients showing the plant is a reasonable, non-superior option for a treatment side effect; and a real, specific, mechanistically plausible interaction risk with chemotherapy drugs that cuts against unsupervised use rather than for it. All of that is true at once. None of it adds up to a cancer treatment, and the gap between “biologically active” and “clinically effective against this disease” is exactly where oncology drug development spends most of its time and money failing, for compounds with far more preclinical support than this one currently has.

Back to Table of Contents

What a Real Cancer Trial Would Need to Show

Naming this is more useful than simply saying “more research is needed,” because it makes clear the tools exist and have simply never been pointed at this specific question. A trial that would actually answer whether this plant treats cancer would need: a defined cancer type and stage; a standardised, dosed, quality-controlled extract or isolated compound rather than home-blended leaf juice of unknown concentration; a comparator arm receiving standard oncology care; an endpoint oncology already trusts — objective tumour response by RECIST criteria, progression-free survival, or overall survival, not a laboratory marker or a symptom score; and a sample size large enough to detect a realistic effect size with confidence. The one existing RCT (mucositis) shows this population and this research infrastructure is entirely capable of running such a trial in Thailand or Malaysia. It has simply never been aimed at the tumour itself.

Back to Table of Contents

Key Research Papers

All links are live PubMed searches rather than fixed records, pre-checked to confirm each one returns the intended paper.

  1. Hii LW et al., “The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma”, BMC Complementary and Alternative Medicine, 2019 — read the conclusion directly: “inefficacious as monotherapy.”
  2. Widjaja SS et al., “Enhanced cytotoxic effects of Clinacanthus nutans and doxorubicin in combination toward breast cancer cell lines”, Journal of Advanced Pharmaceutical Technology & Research, 2021.
  3. Nik Abd Rahman NMA et al., “Antitumor and antioxidant effects of Clinacanthus nutans Lindau in 4T1 tumor-bearing mice”, BMC Complementary and Alternative Medicine, 2019 — the mouse breast-tumour dosing study.
  4. Huang D et al., “Clinacanthus nutans (Burm. f.) Lindau Ethanol Extract Inhibits Hepatoma in Mice through Upregulation of the Immune Response”, Molecules, 2015 — the mouse liver-tumour study with the Th1 cytokine shift.
  5. Kongwattanakul S et al., “Prophylactic management of radiation-induced mucositis using herbal mouthwash in patients with head and neck cancer: an assessor-blinded randomized controlled trial”, Journal of Complementary and Integrative Medicine, 2022 — the one real RCT in cancer patients; trial registration NCT03359187.
  6. Quah SY et al., “Cytotoxicity and cytochrome P450 inhibitory activities of Clinacanthus nutans”, Drug Metabolism and Personalized Therapy, 2017 — the chemotherapy-interaction mechanism.
  7. Ismail F et al., “SF1, a Standardised Fraction from Clinacanthus nutans Modulates Notch1 Signalling in Cervical Cancer Stem-Like Cells”, Malaysian Journal of Medical Sciences, 2025.
  8. Lin CM et al., “Recent Advancement in Anticancer Activity of Clinacanthus nutans (Burm. f.) Lindau”, Evidence-Based Complementary and Alternative Medicine, 2021 — a comprehensive review of the cell-culture and mouse literature.
  9. Cheng YL et al., “Clinacanthus nutans in modern therapeutics: pharmacological insights and emerging clinical applications”, Journal of Asian Natural Products Research, 2026 — a current review that itself concludes clinical validation is still required.
  10. Johnson SB et al., “Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers”, JAMA Oncology, 2018 — the registry study behind the delay/refusal harm figures.
  11. Han E et al., “Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes”, Annals of Surgical Oncology, 2011.
  12. Hamed Abdalla MEA et al., “The use of complementary and alternative medicine (CAM) among cancer patients at a tertiary hospital in Malaysia”, Complementary Therapies in Medicine, 2020 — general Malaysian CAM-use context, not species-specific.
  13. Clinacanthus nutans, cancer, and clinical trials — run the search yourself and see how much of the return is cell culture.

Connections

Back to Table of Contents